Corona Remedies sets launch window for mainboard IPO amid pharma expansion

Corona Remedies’ ₹500 crore IPO opens December 8–10 with a ₹1008–1062 price band, aiming to fund pharma expansion ahead of its December 15 listing.

neutral
Recently

Corona Remedies sets launch window for mainboard IPO amid pharma expansion

1 min read63 words
Corona Remedies sets launch window for mainboard IPO amid pharma expansion
Corona Remedies’ ₹500 crore IPO opens December 8–10 with a ₹1008–1062 price band, aiming to fund pharma expansion ahead of its December 15 listing.
Corona Remedies will open its mainboard IPO from December 8 to 10, targeting ₹500 crore through a fresh issue priced at ₹1008–1062 per share. The company plans to fund capacity expansion and product development initiatives. Allotment is scheduled for December 11, with listing on December 15. Grey market signals indicated a premium of around 15%, reflecting early investor interest in the healthcare segment.
Sentinel